Fox Chase Cancer Center

Fox Chase Cancer Center

Fox Chase Cancer Center was founded in 1904 as the nation's first cancer hospital, originally chartered as the American Oncologic Hospital. It merged with the Institute for Cancer Research in 1974 to create a combined entity that received National Cancer Institute (NCI) Comprehensive Cancer Center designation that same year — one of the earliest institutions to hold that status. The center joined the Temple University Health System in 2012 while retaining its distinct campus and NCI designation, a hybrid governance structure uncommon among independent cancer centers. Programmatically, Fox Chase spans basic laboratory science, early-phase clinical trials, surgical oncology, radiation oncology, and population-science research. Its research funding base exceeds $100 million annually, drawn from NCI grants, pharmaceutical partnerships, and philanthropic support. The center runs a Cancer Prevention and Control program, a Molecular Therapeutics program, and an Immune Cell Regulation and Targeting program — three NCI-evaluated scientific engines that shape its trial portfolio. Key clinical work includes studies in prostate cancer, breast cancer, and lung cancer. Fox Chase's partnership with Temple feeds patients into a health system with roughly 1,300 licensed beds, while the center itself employs over 2,000 staff and maintains an independent faculty of more than 280 physicians and scientists. Institutional scale is reflected in its physical plant: a roughly 100-bed inpatient hospital on the main Philadelphia campus, supplemented by outpatient centers in Buckingham and East Norriton, Pennsylvania. The center has no disclosed endowment or investment portfolio beyond its operating reserves and research grants. Philanthropic giving flows through the Fox Chase Cancer Center Foundation, a registered 501(c)(3). In June 2023, the center announced a $50 million gift from the Estate of Marvin and Concetta Galand — one of the largest individual donations in its history — directed toward research infrastructure (per the center's official communications, 2023). Fox Chase's research posture distinguishes it from most academic medical centers that house cancer programs inside larger university hospitals. It operates under an NCI-funded Cancer Center Support Grant that mandates rigorous external peer review of all scientific programs every five years, a governance forcing-function that elevates investigator-driven trials over volume-driven care. The Temple affiliation supplies a clinical funnel without diluting the center's independent peer-review cycle — a structural arrangement that few NCI-designated centers replicate.